Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing
11 avr. 2024 08h00 HE
|
Bionano Genomics
Researchers used optical genome mapping in addition to whole genome sequencing in pediatric leukemia samples and identified additional structural variants.
Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia
17 août 2022 07h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with Aru Narendran, MD, PhD, Professor,...
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
16 août 2021 19h55 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LONDON , Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the London-based Great Ormond Street Hospital...
Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL
03 sept. 2019 02h00 HE
|
Autolus Therapeutics plc
Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete...
Autolus Therapeutics to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8
02 août 2019 09h06 HE
|
Autolus Therapeutics plc
LONDON, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Participate in Upcoming Investor Conferences in June
28 mai 2019 16h55 HE
|
Autolus Therapeutics plc
LONDON, May 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress
14 mai 2019 06h30 HE
|
Autolus Therapeutics plc
LONDON, May 14, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on May 14
07 mai 2019 16h05 HE
|
Autolus Therapeutics plc
LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Announces Proposed Public Offering in the United States
08 avr. 2019 16h40 HE
|
Autolus Therapeutics plc
LONDON, April 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Oncology Startup Notable Labs Donates its First Pediatric Therapy to Repurposing Non-Profit
22 janv. 2019 10h00 HE
|
Notable Labs
FOSTER CITY, Calif., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Notable Labs, a startup that accelerates drug development by matching drugs with patients who are most likely to respond, announced today that...